on behalf of the RevElution Investigators ABSTRACT OBJECTIVES This study sought to assess the safety and effectiveness of the drug-filled stent (DFS) (Medtronic, Santa Rosa, California) in the treatment of patients with coronary artery disease.
Second-generation DES utilize more biocompatible polymers with reduced inflammation, improved healing, and lower rates of ST and repeat revascularization compared to first-generation DES (11) (12) (13) (14) (15) . Partly as a result, the mandatory duration of dual antiplatelet therapy (DAPT) after DES implantation has recently been reduced in societal guidelines from 12 to 6 months in patients with stable ischemic heart disease (16, 17) .
However, longer duration DAPT decreases the risk for ischemic events even with second-generation DES, and as such the optimal duration of DAPT remains controversial (18) . In addition, all polymer coatings on DES are prone to bonding, webbing, cracking, and peeling during stent expansion and delivery, defects that may serve as a thrombogenic nidus and decrease the uniformity of drug delivery, resulting in thrombosis or restenosis (19, 20) . A polymer-free metal surface stent that is capable of controlled antiproliferative drug elution may avoid the adverse effects of polymerinduced inflammation, thrombosis, and nonuniformity, and could potentially allow for a shorter DAPT duration (21) .
The polymer-free drug-filled stent (DFS) (Medtronic, Santa Rosa, California) was designed to provide controlled and sustained drug elution from an internal stent lumen without utilization of a polymer coating. We herein report the primary endpoint results from the Medtronic RevElution trial, the first-inhuman clinical experience with the DFS.
METHODS DEVICE DESCRIPTION.
The polymer-free DFS is formed from a trilayered wire with the inner core material removed to create a continuous lumen within the stent structure that is coated throughout with sirolimus. The middle layer is tantalum, which enhances radiopacity, whereas the outer layer of cobalt chromium maintains stent strength despite a thin strut thickness of 81 mm. Based on a drug density of w1.1 mg/mm 2 and the circumferential outer stent surface area, the total drug load is 99 mg for a 3.0 mm diameter Â 18 mm long stent. Small laser-drilled holes (w20 mm diameter, w6 per strut, w1,800 holes for an 18 mm stent) on the abluminal surface of the stent determine the rate of drug elution directly into the arterial wall ( Figure 1) .
STUDY DESIGN. The RevElution trial planned to enroll 100 patients at 14 sites in Australia, Latin America, and Singapore to evaluate the clinical safety and efficacy of DFS for the treatment of de novo coronary lesions (Online Table 1 The antiproliferative drug sirolimus coats the internal lumen of the stent (left). The drug elution is controlled and sustained through natural diffusion from abluminal holes (center) via direct interaction with the vessel wall (right).
FIGURE 2 RevElution Study Design
The 9-month cohort is presented in the current analysis. Angio ¼ angiography; IVUS ¼ intravascular ultrasound; OCT ¼ optical coherence tomography; RVD ¼ reference vessel diameter. (22, 23) . The present report describes results through 9 months in the 9-month cohort, all of whom were enrolled in Australia. DFS ¼ drug-filled stent(s). ANGIOGRAPHIC AND IVUS OUTCOMES. Nine-month angiographic and IVUS outcomes are shown in Table 2 . The primary endpoint, in-stent late lumen CLINICAL OUTCOMES. Usage of DAPT at 1 and 9 months was 100% and 93.8%, respectively. One non-Q-wave MI occurred on day 263 post-implant in a subject with lung cancer while undergoing a CTguided lung biopsy. Elevated biomarkers were noted after the biopsy with a normal ECG. Angiography was not performed. There were no target lesion or target vessel revascularizations, no definite or probable stent thromboses, and no deaths. Thus, the 9-month rates of TLF, major adverse cardiac events, and TVF were all 2.1% ( Table 4) .
DISCUSSION
This first clinical experience with the novel polymerfree DFS demonstrates low 9-month in-stent late OCT ¼ optical coherence tomography.
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